A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol

Lignende værker

• Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol
  af: Blum, Kristie A., et al.
  Udgivet: (2011)
• Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
  af: Stephens, Deborah M., et al.
  Udgivet: (2012)
• Reduced Occurrence of Tumor Flare with Flavopiridol Followed by Combined Flavopiridol and Lenalidomidein Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
  af: Maddocks, Kami, et al.
  Udgivet: (2015)
• Outcome of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Genetic Features
  af: Woyach, Jennifer A., et al.
  Udgivet: (2012)
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
  af: Phelps, Mitch A., et al.
  Udgivet: (2009)